Document is current
Any future updates will be listed below
-
Authors
Li, Shuai
Pan, Zongying
Chen, Ruilin
Xu, Shumei
Wang, Yajie
Zeng, Guilin
Li, Yamao
He, Lang
-
Funding
Funding for this research was provided by:
the Sichuan Provincial Health Commission project (24LCYJPT12)
Chengdu Science and Technology Bureau (2025-YF09-00035-SN)
Chengdu Health Commission project (2024091)
Beijing Kangmeng Charity Foundation-Health Development Promotion Project (BJHA-CRP-029)
Joint Innovation Fund Project of University and College (LH202402001)
Beijing Science and Technology Innovation Medical Development Foundation Project (KC2023-J-0288-PM35)
Project for Cell and Immunotherapyof the Fifth People’s Hospital of Chengdu City (XJ2024001801)
- License Information
-
More Information
Article History
Received: 28 December 2025
Accepted: 6 May 2026
First Online: 13 May 2026
Declarations
:
: The authors declare no competing interests.
: This study has been approved by the Ethics Committee of the Fifth Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. Additionally, it has been registered in the Chinese Clinical Trial Registry (ChiCTR), with the registration number ChiCTR2400080841 (available at: ). The study was initiated on February 8, 2024.
: The patient had consented to our candid discussion regarding the patient’s health condition and had authorized the dissemination of such de-identified clinical information in a published format, in line with the ethics approval requirements.
